NEW YORK (GenomeWeb) – GenDx announced today that it has signed a global reseller agreement, giving it the rights to offer Thermo Fisher Scientific's Ion Torrent next-generation sequencing systems and consumables as part of a human leukocyte antigen (HLA) typing workflow used in transplant diagnostics.
Under the terms of the agreement, Netherlands-based GenDx and its distributors can provide the Ion PGM, S5, and Chef systems to customers alongside GenDx's HLA-NGSgo reagents and NGSengine software.
In recent years, NGS-based HLA typing has started to gain momentum, with Illumina and CareDx making deals in the space. GenDx has acquired CE-IVD marking for its HLA typing workflow for the Illumina MiSeq, NGSengine software product, and for its Sanger sequencing-based workflow. The firm said in a statement that it has begun the process of getting the CE mark for NGSgo on the Ion Torrent platform.
"We have evaluated the HLA typing results with the NGSgo full workflow strategies on multiple NGS platforms," GenDx CEO Wietse Mulder said in a statement. "The Ion PGM and Ion S5 systems provide reliable typing results that are of high resolution and phasing comparable to other NGS platforms on the market."
Financial and other terms of the agreement were not disclosed.